Clinical trialPhase 1 / Phase 2Not yet recruiting
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
A Phase Ib/II, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SY-5933 Tablets in Combination With CT-707 Tablets in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- June 2025
- Expected end
- December 2028
- Enrollment
- 102 participants
- Sites
- 1
- Primary outcomes
- Incidence of adverse events (AEs) and serious adverse events (SAEs) in KRAS p.G12C Mutant Advanced Solid Tumors in Phase Ib; Dose-limiting toxicity (DLT) of SY-5933 combined with CT-707 in KRAS p.G12C Mutant Advanced Solid Tumors in Phase Ib; Objective response rate (ORR) of SY-5933 combined with CT-707 in KRAS p.G12C Mutant Advanced Solid Tumors in Phase II
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 May 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This Phase Ib/II, open-label, single-arm study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of SY-5933 tablets combined with CT-707 tablets in patients with advanced solid tumors harboring the KRAS p.G12C mutation. The Phase Ib includes a dose-escalation phase to determine the optimal dosing regimen based on safety and pharmacokinetic data. In Phase II, four cohorts will be enrolled: advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other solid tumors.
Detailed description public domain (ClinicalTrials.gov)
This is an open-label, single-arm Phase Ib/II trial to assess the combination of SY-5933 and CT-707 in KRAS p.G12C mutated advanced solid tumors. In Phase Ib, six patients will receive 800 mg of SY-5933 and 600 mg of CT-707 once daily (QD) in a dose-escalation design, with dose adjustments based on safety, pharmacokinetic and efficacy data. The Ib expansion phase will further investigate the most promising dose/frequency combinations. In Phase II, four cohorts will be treated: advanced NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors with KRAS p.G12Cmutation. Efficacy will be evaluated through interim analyses based on objective response rate. Patients will be treated until disease progression, unacceptable toxicity, death, or study completion.